| Literature DB >> 31294654 |
Sabah Mayahi1,2,3, Masood Golalipour3, Ahad Yamchi4, Gagan Deep Jhingan5, Majid Shahbazi3,6.
Abstract
Background: The forkhead box O3 (FOXO3) and p27Kip1 are two important genes in breast cancer progression. In the present study we analyzed the effect of simultaneous FOXO3 silencing and p27Kip1 activation on breast cancer cell survival and the potential targets of these changes in cancer molecular pathways. Materials and methods: The present study involved the cloning of FOXO3a shRNA and p27Kip1 genes under the control of the bidirectional survivin promoter to down- and up-regulate FOXO3 and p27Kip1 genes, respectively. After transfection of the recombinant expression vector into the breast cancer cell line, the inhibition of cell growth was assessed by MTS and flow cytometry assays. Following the extraction of total mRNA and protein, the expression of target genes was evaluated by qPCR and Western blotting in both treated and untreated cell lines. Then, the downstream protein responses were examined by 2 D electrophoresis. The differentially expressed proteins were also identified by mass spectrometry.Entities:
Keywords: Breast cancer; FOXO3a; P27Kip1; cell signaling; gene therapy; proteomics
Mesh:
Substances:
Year: 2019 PMID: 31294654 PMCID: PMC6758695 DOI: 10.1080/03009734.2019.1623351
Source DB: PubMed Journal: Ups J Med Sci ISSN: 0300-9734 Impact factor: 2.384
Figure 1.(A) Map of pcDNA3.1(+) EGFP; (B) pSur (shFOXO3-p27Kip1) vector with a survivin promoter.
Primers used in this study.
| Primer | Sequence (5’→3’) |
|---|---|
| FOXO3a (R) | GACTATGCAGTGACAGGTTGTG |
| FOXO3a (F) | TCTACGAGTGGATGGTGCGTT |
| P27 (R) | TCCATTCCATGAAGTCAGCG |
| P27 (F) | GAGCAGACGCCCAAGAAGC |
| GAPDH (R) | AGGCAGGGATGATGTGGAGAG |
| GAPDH (F) | ATCGTGGAACTCAGTACCACA |
Figure 2.Relative expression of FOXO3 and p27Kip1 genes in the MDA-MB-231 cell line after transfection was significantly down-regulated and up-regulated, respectively, 72 h after transfection. Expression of the genes was analyzed by the REST program (P < 0.05).
Figure 3.Relative band densitometry of Western blotting data, showing: (A) the incidence of the highest down-regulation of FOXO3a gene 72 h after transfection; (B) reduction of FOXO3a gene expression in the cells treated with the construct after 72 h, compared to the control; (C) the highest up-regulation of P27Kip1 gene in MDA-MB-231 cells occurring 72 h post-transfection; and (D) an increase in P27Kip1 expression in the cells treated with the construct 72 h after transfection, compared to the control. Implementation of quantification in three repeats (GAPDH was used as the control).
Figure 4.Microscopic morphology of MDA-MB-231 cells under a fluorescent microscope after transfection for 24 h, 48 h, and 72 h with: (A) an empty vector; (B) a vector containing the genes after 24 h, (C) 48 h, (D) 72 h; and (E) negative signal of control cells without transfection.
Figure 5.Inhibition of MDA-MB-231 cell proliferation after 24 h, 48 h, and 72 h of treatment in wells (in triplicate) using MTS assay. Data are expressed as the mean cell viability percentage versus that of the control.
Figure 6.Apoptosis detection via flow cytometry. A: use of Annexin V-FITC staining in the treated and untreated MDA-MB-231 cells after 24 h, 48 h, and 72 h. The upper and lower right quadrants (Annexin V+/PI + and Annexin V+/PI−, respectively) indicate late and early apoptosis, respectively (10.4% of cells died by lipofectamine, as shown in Supplementary Figure 1, available online). B: Apoptosis in the treated and control MDA-MB-231 cells 24 h, 48 h, and 72 h post-transfection. Data were presented as mean ± SD (P < 0.05).
Figure 7.Two-dimensional gel electrophoresis of MDA-MB-231 cell line in treated and untreated cells, showing the increased expression of tubulin beta chain, vimentin (three isoforms), and β-actin (two isoforms) and decreased expression of succinate dehydrogenase complex, albumin, and NLK. Protein spots 6 and 7 were absent in the treated cells. The experiment was performed in two biological repeats. A = absence.
Protein spots collected from two-dimensional gels in MDA-MB-231 cell line transfected with the plasmid construct in comparison with the control (empty vector) after 72 h.
| Spot ID | Accession | Name of protein | Gene | Theoretical MW (kDa)/PI | Experimental MW (kDa)/PI | Ratio | Peptide | Score |
|---|---|---|---|---|---|---|---|---|
| 1 | P31040 | Succinate dehydrogenase | SDHA | 72.6/7.39 | 72.2/7.8 | 2.1 (up-regulated) | VGSVLQEGGK | 2.65 |
| 2 | Q9BQE3 | α-Tubulin | TUBA1C | 51/6.0 | 49.9/7.1 | 0.2 (down- regulated) | AVFVDLEPTVIDEVR; EIIDLVLDR; EDAANNYAR; DVNAAIATIK; TIGGGDDSFNTFFSETGAGK; LSVDYGKK; LSVDYGK | 12.49 |
| 3 | P02768 | Albumin | ALB | 69.3/6.28 | 65.1/6.5 | 1.2 (up-regulated) | KVPQVSTPTLVEVSR; AEFAEVSK; LVTDLTK | 2.49 |
| 4 | Q9UBE8 | Serine/threonine-protein kinase NLK | NLK | 8.13/58.28 | 34..6/8.7 | 4.5 (up-regulated) | TQEVVTQYYRAPEILMGSRHYSNAIDIWSVGIFAELLGR; PNVFQNLVSCK; ICDFGLARVEELDESR | 2.6 |
| 5 | P08670 | Vimentin | VIM | 53.65/5.12 | 49.8/5.5 | 0.3 (down-regulated) | QDVDNASLAR; QVQSLTEVDALK; VELQELNDR; QQYESVAAK; EEAENTLQSFR; ETNLDSLPLVDTHSK; EYQDLLNVK; LQEEMLQR; | 19.82 |
| 6 | P08670 | Vimentin | VIM | 53.65/5.12 | 52.5/5.7 | a/p (down-regulated) | EEENFAVEAANYQDTIGR; ALDIEIATYR; EKLQEELQR; QVQSLTEVDALK; QDVDNASLAR; VESLQEEIAFLK; VELQELNDR; EEAENTLQSFR; ETNLDSLPLVDTHSK; QQYESVAAK; LQEEMLQR; LLEGEESR; DNLAEDIR; QVDQLTNDK | 35.71 |
| 7 | P08670 | Vimentin | VIM | 53.65/5.12 | 50.4/5.6 | a/p (down-regulated) | VELQELNDR; FADLSEAANR; QYESVAAKLGDLYEEEMR; EAENTLQSFR; ALDIEIATYR; LQEEMLQR; QESTEYR; ETNLDSLPLVDTHSK; QVQSLTEVDALK; LGDLYEEER; DNLAEDIR; LLEGEESR; LQDEIQNKEEAR; FANYIDK | 27.58 |
| 8 | P60709 | β-Actin | ACTB | 41.7/5.48 | 40.5/6.5 | 0.2 (down-regulated) | QEYDESGPSIVHR;GYSFTTTAER; DLTDYLMK; APEEHPVLLTEAPLNPK; DSYVGDEAQSKR; DSYVGDEAQSK; EITALAPSTK; DLTDYLK; DLYANTVLSGGTTYPGIADR | 17.02 |
| 9 | P60709 | β-Actin | ACTB | 41.7/5.48 | 40.89/6.7 | 0.1 (down-regulated) | QEYDESGPSIVHR;GYSFTTTAER; DLTDYLMK; APEEHPVLLTEAPLNPK; DSYVGDEAQSKR; DSYVGDEAQSK; EITALAPSTK; DLTDYLK; DLYANTVLSGGTTYPGIADR | 10.72 |
| 10 | P07437 | Tubulin beta chain | TUBB | 51.2/5 | 49.6/5.8 | 0.3 (down-regulated) | INTFSVVPSPK; TAVDIPPR; ISVYYNEATGGK; NAADPR; LAVNVPFPR | 46.38 |
a/p: absence/presence; MW: molecular weight.
Protein–protein interactions of all proteins for collecting the data.
| Gene | |||||||
|---|---|---|---|---|---|---|---|
| Vim | ACTB | TUBA1C | TUBB | SDHA | NLK | ALB | |
| Expand | |||||||
| Physical interaction | SERPINH, MAGOH, EIFA3, SPRM4, KRT18, UPP1, ITGB4, BASP1, PPL, URGDP, XPNPEP3 | CFL1, CFL2, PFN1, CCT8, TCP1, CCT3, CCT4, RUVBL1, MYH11 | TUBA4B, TUBB6, TUBB, TUBA4A, TUBB4A, TUBB4B, TUBB3, TUBB2A, TUBB6, TUBB2B, GAPDH, | THBS1, CLIP1, TCP11L1, TUBB2A, YBX1, TUBA1A, TUBA1B, TUBA1C, TUBA1A, TUBA4B, PNKD, TNPO2, DNAJA4 | SLC2A14, CPNE1, RAB14, LRRC8A, HIGD1A, SDHAF2, SDHAF2, SDHC, SDHB, UBC | MYB, RANGAP1, ZHX3, MAP3K7, TAB1, HIPK2, LEF1, TP53, TCF7L2 | F2, HP, ITIH1, AMBP, AHSG, APOA2, RBP4, FCGRT |
| Co-expression | SERPINH, TTN | CFL1, PFN1 | TUBB6, TUBB, TUBA4A, TUBB4B, TUBB3, TUBB2A, TUBB6, TUBB2B, GAPDH, TUBA1A, TUBA1B, TBCB, PFDN1, STMN1 | TUBAB, TUBB2A, TUBG2, YBX1, TUBA1B, TUBA1C, TUBA4A, TUBB3, TUBB4B, TUBG1 | RAB14, HIGD1A, SDHC, SDHB, NDUFV1, UBC, ALAD, UQCRC1 | — | F2, HP, ITH1, GC, AMBP, AFM, AHSG, AFP, APO2, RBP4, SLCO1B1, SLCO1B3 |
| Co-localization | SERPINHI | — | STMN1, TBCB, TUBA1B, TUBA1A, TUBB2A | — | NDUFV1, UQCRC1, NDUFS1 | RANGAP1, MAP3K7, TAB1 | F2, HP, ITH1, GC, AMBP, AHSG, APO2, RBP4, SLCO1B1, SLCO1B3 |
| Gene interaction | — | — | — | — | — | TP53 | — |
| Role | Proliferation, tissue invasion, and metastasis | Cell mobility, endocytosis, cell adhesion, division, drug resistance, and metastasis | Cellular mobility | Cellular mobility | Tumor suppressor | Inhibit cellular proliferation, induce apoptosis | Stabilizing DNA, regulation calcium, antioxidant properties |
Figure 8.Effect of simultaneous FOXO3a suppression and P27Kip1 induction on protein expression in treated cells.